Knight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 10,900 Shares

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 10,900 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of C$5.95, for a total value of C$64,855.00.

Sime Armoyan also recently made the following trade(s):

• On Monday, April 1st, Sime Armoyan acquired 6,200 shares of Knight Therapeutics stock. The shares were bought at an average cost of C$5.25 per share, with a total value of C$32,550.00.
• On Monday, March 25th, Sime Armoyan acquired 351,000 shares of Knight Therapeutics stock. The shares were bought at an average cost of C$5.25 per share, with a total value of C$1,842,750.00.
• On Monday, January 22nd, Sime Armoyan sold 28,200 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.75, for a total value of C$162,150.00.
• On Friday, January 19th, Sime Armoyan sold 91,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.75, for a total value of C$523,250.00.

Knight Therapeutics Stock Up 1.1 %

Knight Therapeutics stock opened at C$5.76 on Tuesday. The firm has a market cap of C$582.74 million, a price-to-earnings ratio of -36.00, a PEG ratio of -1,013.50 and a beta of 0.49. The stock has a fifty day simple moving average of C$5.47 and a two-hundred day simple moving average of C$5.23. Knight Therapeutics Inc. has a 12 month low of C$4.35 and a 12 month high of C$5.95. The company has a current ratio of 3.20, a quick ratio of 1.79 and a debt-to-equity ratio of 9.25.

Knight Therapeutics (TSE:GUD) last posted its earnings results on Thursday, March 21st. The company reported C($0.03) EPS for the quarter, missing analysts’ consensus estimates of C$0.02 by C($0.05). The business had revenue of C$74.20 million during the quarter, compared to the consensus estimate of C$78.37 million. Knight Therapeutics had a negative return on equity of 2.14% and a negative net margin of 5.13%. Equities analysts predict that Knight Therapeutics Inc. will post 0.0202158 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on GUD. Royal Bank of Canada raised their price objective on Knight Therapeutics from C$6.50 to C$7.00 and gave the company an “outperform” rating in a research report on Friday, March 22nd. Raymond James lifted their target price on Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an “outperform” rating in a report on Wednesday, March 6th.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.